iPROVE Network Research Group www.iprove-network.es



PEAL + iPROVE-ELA

Individualized PeriopeRative Open lung VEntilatory approach in Emergency Abdominal Laparo-tomy/scopy. A prospective multicenter randomized controlled trial

Investigator Information Brochure PEAL + iPROVE-EAL



A) Dissemination of research results and sub-studies

The Scientific Committee will appoint a Drafting Committee to draft the scientific report (s) of this research, which will be disseminated in a timely manner. It is expected that a series of secondary analyzes will be carried out. Researchers will have priority to direct this type of analysis and are encouraged to do so. Participation will be based on the contribution to the study in its two phases. The Steering Committee will take into account the scientific validity and the possible effect on the anonymity of the participating centers before the granting of any of these applications. If necessary, a prior written agreement will establish the terms of this type of collaboration. The Scientific Committee must approve the final version of all manuscripts, before submission. In case of disagreement within the Steering Committee, the head of the investigation will make a decision. Any data from the PEAL and iPROVE-EAL analysis with the incorporation of two or more study sites will be taken into account for possible secondary analyzes and will be subject to predefined rules.

All participants in the study will be included as co-authors under the iPROVE Research Network Group.

Authorship for the PEAL study

The main manuscript will be signed as iPROVE Research Network Group. All the secondary analysis, proposed by the Scientific Committee or researchers from participant hospitals, will always include the iPROVE Research Network Group.

Each participant hospital can include one author every 3 included patients.

Authorship for the iPROVE-EAL study

The authorship regulations will be specified once the final sample size has been calculated and the number of participating centers closed.

B) eCRF for the PEAL Project.

The data collected must be uploaded to the corresponding online CRF for final data collection.

Register as a center in eCRF



First of all, one must register as a participating center in the study by sending an email with the subject "Register RedCap PEAL study" in which the name and surname must be included as well as the email address that we wish to use for this service. This email must be sent to the address sau@clinic.cat

If you do not receive a response in the following 48 hours, please contact the corresponding managers listed on the contact page that we can find on the website <u>http://www.iprove-network.es</u> in the "PEAL" section.

Enter or modify data in eCRF

P To enter the data we must enter the eCRF section of the website or directly at the address <u>http://www.redcap.clinic.cat</u>. At this point we must enter the username and password that we received when registering as a center in the eCRF.

REDCap	Home I My Projects	ex.php?action=r	Send-It 📮	Messe	enger						
			users still have	access	REDCap projects to which you currently have access to your projects. visit the <u>User Access Dashboard</u> .	. Click the project title t					
			My Projects		Songanize Collapse All				s by title	×	B
			Project Title				Records	Fields	Instruments	Туре	Status
				aoperat	torio de Transplante Hepático		Records	Fields 234	Instruments 13 forms 1 aurity	Type 8	Status 🕑
				soperat	torio de Transplante Hepático						



We will enter the **"PEAL"** section and once inside we will go to the **"Add/Edit Records"** section. If we want to modify a previous record, we must mark in **"Choose an existing Patient ID"** the record number of the included patient in question. We will mark in **"Add new record"** if we want to introduce a new record.

We recommend saving the Patient ID of the patients entered in case you need to recover or modify the previous ones.



🖥 Add / Edit Records					
'ou may view an existing record/response by selow.	selecting it from the o	Jrop-down lists below. To create	a new record/res	ponse, click the button	
Total records: 0					
Choose an existing Patient ID		select record 🗸			
		+ Add new record			
Data Search					
	All fields	~			
Choose a field to search (excludes multiple choice fields)					

In each of the sections covered we will have at our disposal explanatory videos that will show us how data collection works and the corresponding entry in this eCRF.

C) Study website and online randomization (iPROVE-EAL)

In order to facilitate various procedures for researchers, the PEAL and the iPROVE-EAL trial makes available the website (<u>www.iprove-network.es</u>) from which it is possible to download patient information sheets, data collection notebooks and other documentation of interest related to the project.

The randomization of patients (iPROVE-EAL) must be done through an online application which <u>is accessed</u> from the website, in the section "RANDOMIZATION AREA". To enter it, the user must enter with their own password provided. Then, clicking on the link "Access to the randomization application" the website will launch a form where the center code that was provided and the patient code should be written according to the established coding. Pressing the button will execute the randomization that will be stored in the database, and the result of the group to which the patient has been assigned will appear on the screen, with the option of printing it. <u>IMPORTANT: Only one randomization per patient must be done through the web application.</u> Launching the application more than once for the same patient code can lead to errors in the subsequent analysis of the results of the data collected in your center. To avoid errors, there is a link which can be used to perform randomization tests without sending or storing results.



- The code of your center is the same user with which the private area is accessed.

- The patient code has the structure "pac", followed by a 3-digit number that represents the number of the patient recruited in your center. For example: pac-002, pac-123 ... On this website, you can also download paper data collection forms. However, once completed, the researcher must download the digital data collection forms, in Microsoft Word format, prepared to facilitate the entry of paper data into electronic format.

D) Definition of complications

Pulmonary Complications	PEAL + iPROVE-EAL
Atelectasis	Combination of SpO ₂ \leq 96% during the air test and chest radiography with lung opacification with shift of the mediastinum, hilum, or hemidiaphragm towards the affected area, and compensatory overinflation in the adjacent non-atelectatic lung
Hypoxemia or Mild respiratory failure	SpO ₂ < 92% or PaO ₂ < 300mmHg with FiO ₂ of 0.21
Severe respiratory failure	Increased FiO ₂ , increased requirement for CPAP, or the need for noninvasive or invasive ventilation
Weaning failure	Reintubation within the first 48h after postoperative extubation.
	• Mild: $PaO_2/FiO_2 < 300 \text{ mmHg with } CPAP \ge 5 \text{ cmH}_2O \text{ y } FiO_2 \ge 0.5.$
	• Moderate: $PaO_2/FiO_2 < 200 \text{ mmHg with } PEEP \ge 5 \text{ cmH}_2O \text{ y } FiO_2 \ge 0.5.$
ARDS	• Severe: $PaO_2/FiO_2 < 100 \text{ mmHg with } PEEP \ge 5 \text{ cmH}_2O \text{ y } FiO_2 \ge 0.5.$
	Acute (within one week) symptoms with bilateral pulmonary opacities
Pulmonary infection	Presence of a new pulmonary infiltrate and/or progression of previous pulmonary infiltrates on a chest radiograph plus at least two of the following criteria: (a) leukocytosis with > 12,000 WBC/mm ³ or leukopenia with < 4000 WBC/mm ³ , (b) fever > 38.5°C or hypothermia < 36°C, and (c) increased secretions with purulent sputum and a positive bronchial aspirate
Pleural effusion	Chest radiography with the presence of costophrenic angle blunting, displacement of adjacent anatomical structures, and blunting of the hemidiaphragmatic silhouette in the supine position
Pneumothorax	Chest radiography with air in the pleural space with no vascular bed surrounding the visceral pleura
Bronchospasm	Presence of expiratory wheezing treated with bronchodilator
Aspiration pneumonitis	Respiratory failure after the inhalation of regurgitated gastric contents
Pulmonary edema	Fluid accumulation in the alveoli due to poor cardiac function diagnosed with chest radiography of lung ultrasound.
Pulmonary embolism	A new blood clot or thrombus within the pulmonary arterial system.



Systemic Complications	PEAL + iPROVE-EAL
Severe sepsis	Infectious focus identified plus organ dysfunction (defined as an increase in SOFA ≥2).
Septic shock	Severe sepsis with hypotension and hypoperfusion that is unresponsive to fluids.
Surgical site infection	 The CDC defines a superficial incisional surgical site infection as one which meets the following criteria. (1) Infection occurs within 30 days after surgery and (2) Involves only skin and subcutaneous tissue of the incision and (3) The patient has at least one of the following: (a) purulent drainage from the superficial incision (b) organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision (c) at least one of the following symptoms or signs of infection: pain or tenderness, localised swelling, redness or heat, and superficial incision is deliberately opened by surgeon and is culture positive or not cultured. A culture negative finding does not meet this criterion. (d) diagnosis of an incisional surgical site infection by a surgeon or attending physician.
Urinary tract infection	A simplified version of the CDC recommendations defines a urinary tract infection as follows: a positive urine culture of 105 colony forming units ml1 with no more than two species of microorganisms, and with at least one of the following symptoms or signs: fever (> 38.8°C), urgency, frequency, dysuria, suprapubic tenderness, costovertebral angle pain or tenderness with no other recognised cause.
Arrhythmia	ECG evidence of cardiac rhythm disturbance.
Myocardial infarction	Increase in serum cardiac biomarker values (preferably cardiac troponin) with at least one value above the 99th percentile upper reference limit and at least one of the following criteria:10 symptoms of ischaemia; new or presumed new significant ST segment or T wave ECG changes or new left bundle branch block; development of pathological Q waves on ECG; radiological or echocardiographic evidence of new loss of viable myocardium or new regional wall motion abnormality; identification of an intracoronary thrombus at angiography or autopsy
Heart failure	Cardiac index <2.5 ml/min/m² or >2.5 when ≥5 μg/kg/min dobutamine is required. Clinical signs (hypotension, oliguria, pulmonary edema) together with NT-proBNP >13 pg/ml or echocardiographic diagnosis.
Acute kidney injury	 AKIN scale: Stage I: Diuresis < 0,5 mg/Kg (6h) or increase in serum Cr > 0,3 mg/dl. Stage II: Diuresis < 0,5 mg/Kg (12h) or basal Cr x 2 mg/dL. Stage III: Diuresis < 0,3 mg/Kg (24h) o anuria (12h) or basal Cr x 3 mg/dL, or Cr > 4 mg/dL or renal replacement



	therapy.
Delirium	Positive Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) (see information brochure)
Paralytic ileus	Failure to tolerate solid food or defecate for three or more days after surgery
Postoperative hemorraghe	blood loss within 72 h after the start of surgery which result in transfusion of blood or a drop in hemoglobin > 7gr/dL Leak of luminal contents from a surgical connection between two hollow viscera. The luminal contents may
Anastomotic breakdown	emerge either through the wound or at the drain site, or they may collect near the anastomosis, causing fever, abscess, septicemia, metabolic disturbance and/or multiple organ failure. The escape of luminal contents from the site of the anastomosis into an adjacent localized area, detected by imaging, in the absence of clinical symptoms and signs should be recorded as a subclinical leak.

E) Scales and calculations

ASA physical status classification system

ASA I	A normal healthy patient. Healthy, non-smoking, no or minimal alcohol use
ASA II	A patient with mild systemic disease. Only mild diseases without substantive functional limitations. Examples include (but not limited to): current smoker, social alcohol drinker, pregnancy, obesity (30 < BMI < 40), well-controlled DM/HTN, mild lung disease
ASA III	A patient with severe systemic disease. Substantive functional limitations; One or more moderate to severe diseases. Examples include (but not limited to): poorly controlled DM or HTN, COPD, morbid obesity (BMI ≥40), active hepatitis, alcohol dependence or abuse, implanted pacemaker, moderate reduction of ejection fraction, ESRD undergoing regularly scheduled dialysis, premature infant PCA < 60 weeks, history (>3 months) of MI, CVA, TIA, or CAD/stents.
ASA IV	A patient with severe systemic disease that is a constant threat to his life. Examples include (but not limited to): recent (< 3 months) MI, CVA, TIA, or CAD/stents, ongoing cardiac ischemia or severe valve dysfunction, severe reduction of ejection fraction, sepsis, DIC, ARD or ESRD not undergoing regularly scheduled dialysis



Body mass index (BMI): Kg/m²

Predicted body weight (PBW):

men: PBW (kg) = 50 + 0.91 (height in cm-152)

women: PBW (kg) = 45.5 + 0.91 (height in cm-152)

	8 ml/kg PBW in	men		8 ml/kg PBW in w	vomen
162 cm	164 cm	166 cm	153 cm	155 cm	157 cm
470 ml	485 ml	500 ml	370 ml	385 ml	400 ml
168 cm	170 cm	171 cm	159 cm	160 cm	161 cm
515 ml	530 ml	535 ml	415 ml	420 ml	425 ml
172 cm	173 cm	174 cm	162 cm	163 cm	164 cm
540 ml	550 ml	560 ml	435 ml	440 ml	450 ml
175 cm	176 cm	177 cm	165 cm	166 cm	167 cm
565 ml	570 ml	580 ml	455 ml	465 ml	470 ml
178 cm	179 cm	180 cm	168 cm	169 cm	170 cm
585 ml	595 ml	600 ml	475 ml	485 ml	490 ml
182 cm	184 cm	186 cm	171 cm	172 cm	174 cm
615 ml	630 ml	645 ml	500 ml	505 ml	520 ml
188 cm	190 cm	192 cm	176 cm	178 cm	180 cm
660ml	670 ml	685 ml	530 ml	550 ml	565 ml



Visual Analog Scale (VAS)

The VAS scale allows to measure the pain intensity that the patient describes with the maximum reproducibility among the observers. It consists of a horizontal line of 10 centimeters, at the ends of which are the extreme expressions of a symptom. On the left is the absence of pain or less intensity. The patient is asked to mark the point indicating the intensity on the line and it is measured with a millimeter ruler. The intensity is expressed in centimeters.

Charlson comorbidity index

Clinical condition	Weight
- Myocardial infarct, Congestive cardiac insufficiency, peripheral vascular disease, cerebrovascular disease.	
- Dementia	
- COPD	
- Ulcers	1
- Conjunctive tissue disease	
- Cirrhosis or chronic disease of the liver	
- Diabetes	
- Hemiplegia	
- Moderate or severe kidney disease	2
- Diabetes with organ complication	2
- Tumor/Leukemia/Lymphoma	
- Moderate or severe liver disease	3
- Malignant tumor, metastasis, AIDS	6



Apfel score for PONV

Risk factors	Points	Risk factors	Points
Female gender	1	Postoperative Opioids	1
Non-smoker	1	Sum=	04
History PONV	1		

SOFA (Sequential Organ Failure Assessment) SCORE

System					
	0	1	2	3	4
Cardiovascular	MAP > 70 mmHg	MAP < 70 mmHg	Dopamine≤5 µg/kg/min or dobutamine (any dose)	Dopamine>5 or epinephrine≤0.1 or norepinephrine ≤0.1	Dopamine>5 or epinephrine >0.1 or norepinephrine >0.1
Respiratory (PaO ₂ /FiO ₂)	>400	301-400	201-300	101-200	≤ 100
Hepatic (bilirrubin,µmol/l	≤ 20	20-32	33-101	102-204	>204
mg/dl	<1.2	1.1-1.9	2.0-5.9	6.0-11.9	>12.0
Kidney (creatinine, µmol/l)	≤110	110-170	171-299	300-440;	>440;
mg/dl	<1.2	1.2-1.9	2.0-3.4	3.5-4.9;	>5.0;
				or	or
				urine output ≤500 ml/d	urine output <200 ml/d
Coagulation (platelets, x 10 ^{3/} microL)	>150	≤150	≤100	≤50	≤20
SNC (Glasgow Coma Scale)	15	13-14	10-12	6-9	<6



ARISCAT Score

	≤ 50	0
Age	51-80	3
	≥80	16
	≥96	0
Preoperative SpO ₂	91-95	8
	≥90	24
Respiratory infection (last month)		17
Preoperative hemoglobin (≥ 10 g/dl)		11
	Peripherical	0
Surgical incision	Abdominal	15
	Intrathoracic	24
	≤2	0
Duration of surgery (h)	> 2 a 3	16
	>3	23
Emergency surgery		8




Richmond Agitation Sedation Scale (RASS)

Score	Term	Description
+4	Combative	Overtly combative or violent; immediate danger for the staff
+3	Very agitated	Pulls on or removes tube(s) or catheter(s) or has aggressive behavior towards staff
+2	Agited	Frequent nonpurposeful movement or patient-ventilator dyssynchrony
+1	Restless	Anxious or apprehensive movements but not aggressive or vigorous
0	Alert and calm	Spontaneously pays attention to caregiver
-1	Drowsy	Not fully alert, but has sustained (more than 10 seconds) awakening, with eye contact, to voice
-2	Light sedation	Briefly (less than 10 seconds) awakens with eye contact to voice
-3	Moderate sedation	Any movement (but no eye contact) to voice
-4	Deep sedation	No response to voice, but any movement to physical stimulation
-5	Unarousable	No response to voice or physical stimulation



CAM-ICU scale





Clinical Fraily Scale

CLINCAL FRAILTY SCALE		
Very fit	Robust, active, energetic, motivated. Exercise regularly.	1.
Well	No active disease symptoms. Exercise or very active occasionally.	2.
Managing well	Well controlled medical problems. Not regularly active (walking).	3.
Vulnerable	Symptoms limit activities, but not dependent on others for daily help.	4.
Mildly frail	Evident slowing and need help in instrumental activities of daily living (controlling medication, finances, transportation, heavy housework). Typically impairs shopping, walking outside alone, meal preparation and housework.	5.
Moderately frail	Need help with all outside activities and housekeeping. Often have problems with stairs and need help with bathing and getting dressed.	6.
Severely frail	Completely dependent for personal care, any physical or cognitive activity. Stable, not at high risk of dying within 6 months.	7.
Very severely frail	Completely dependent, approaching the end of life. Typically, they could not recover from a minor illness.	8.
Terminally ill	Approaching the end of life. Life expectancy < 6 months.	9.